HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors

Nature Immunology

Volumn 3, Issue 11, 2002, Pages 1061-1068

  Migueles, Stephen A ^a   Laborico, Alisha C ^a   Shupert, W Lesley ^a   Sabbaghian, M Shirin ^a   Rabin, Ronald ^b   Hallahan, Claire W ^a   Van Baarle, Debbie ^c   Kostense, Stefan ^c   Miedema, Frank ^c   McLaughlin, Mary ^a   Ehler, Linda ^a   Metcalf, Julia ^a   Liu, Shuying ^a   Connors, Mark ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c CENTRAL LABORATORY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; DIDANOSINE; EFAVIRENZ; HLA ANTIGEN CLASS 1; INDINAVIR; INTERLEUKIN 2; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PERFORIN; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREGULATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; VIRUS REPLICATION;

ADULT; AGED; ANTI-HIV AGENTS; ANTIGENS, CD; ANTIGENS, CD29; ANTIGENS, CD3; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DISEASE PROGRESSION; EXOCYTOSIS; FEMALE; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HIV-1; HIV-2; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PHENOTYPE; PORE FORMING CYTOTOXIC PROTEINS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTE SUBSETS; VIRAL LOAD; VIRUS REPLICATION;

EID: 0036852179     PISSN: 15292908     EISSN: None     Source Type: Journal    
DOI: 10.1038/ni845     Document Type: Article

References (49)

1. McMichael, A. J. & Rowland-Jones, S. L. Cellular immune responses to HIV. Nature 410, 980-987 (2001).
2. Lieberman, J., Shankar, P., Manjunath, N. & Andersson, J. Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood 98, 1667-1677 (2001).
3. Goulder, P. J. et al. Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection. AIDS Res. Hum. Retroviruses 12, 1691-1698 (1996).
4. Kaslow, R. A. et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nature Med. 2, 405-411 (1996).
5. *04 disadvantage. Science 283, 1748-1752 (1999).
6. Flores-Villanueva, P. O. et al. Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proc. Natl. Acad. Sci. USA 98, 5140-5145 (2001).
7. *5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl. Acad. Sci. USA. 97, 2709-2714 (2000).
8. + T cells. Immunol. Lett. 79, 141-150 (2001).
9. + T cells in HIV infected progressors and long term nonprogressors. J. Immunol. 165, 1082-1092 (2000).
10. + responses in HIV type 1-infected patients: comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy. J. Virol. 73, 7108-7116 (1999).
11. + T-cell responses: relationship to viral load in untreated HIV infection. J. Virol. 75, 11983-11991 (2001).
12. + HIV-specific T cells during progression to AIDS. Blood 99, 2505-2511 (2002).
13. Pantaleo, G. et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N. Engl. J. Med. 332, 209-216 (1995).
14. Strathdee, S. A. et al. Lack of consistency between five definitions of nonprogression in cohorts of HIV-infected seroconverters. AIDS 10, 959-965 (1996).
15. Oxenius, A. et al. Distribution of functional HIV-specific CD8 T lymphocytes between blood and secondary lymphoid organs after 8-18 months of antiretroviral therapy in acutely infected patients. AIDS 15, 1653-1656 (2001).
16. + T cells in individuals receiving highly active antiretroviral therapy (HAART). J. Immunol. 162, 1780-1788 (1999).
17. Ogg, G. S. et al. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J. Virol. 73, 797-800 (1999).
18. Ferrari, G. et al. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc. Natl. Acad. Sci. USA 94, 1396-1401 (1997).
19. Shankar, P., Xu, Z. & Lieberman, J. Viral-specific cytotoxic T lymphocytes lyse human immunodeficiency virus-infected primary T lymphocytes by the granule exocytosis pathway. Blood 94, 3084-3093 (1999).
20. + T cells. J. Exp. Med. 186, 1407-1418 (1997).
21. Champagne, P. et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410, 106-111 (2001).
22. + T cells vary in differentiation phenotype in different persistent virus infections. Nature Med. 8, 379-385 (2002).
23. + T lymphocytes. J. Immunol. 167, 181-187 (2001).
24. + pool with distinct phenotypic and migratory characteristics. J. Immunol. 167, 212-220. (2001).
25. Andersson, J. et al. Perforin is not co-expressed with granzyme A within cytotoxic granules in CD8 T lymphocytes present in lymphoid tissue during chronic HIV infection. AIDS 13, 1295-1303 (1999).
26. + T cells and associated with a proliferative response to p24 antigen. J. Virol. 74, 2023-2028 (2000).
27. Goulder, P. J. et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nature Med. 3, 212-217 (1997).
28. Goulder, P. J. et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 412, 334-338 (2001).
29. Kelleher, A. D. et al. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J. Exp. Med. 193, 375-386 (2001).
30. Bachmann, M. F., Barner, M., Viola, A. & Kopf, M. Distinct kinetics of cytokine production and cytolysis in effector and memory T cells after viral infection. Eur. J. Immunol. 29, 291-299 (1999).
31. + T cells. Nature 401, 76-79 (1999).
32. Goulder, P. J. et al. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J. Exp. Med. 193, 181-194 (2001).
33. Kaslow, R. A. et al. Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines. J. Virol. 75, 8681-8689 (2001).
34. + T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 18, 332-340 (1998).
35. + lymphopenia. J. Infect. Dis. 185, 1401-1416 (2002).
36. + T cells from HIV-infected persons. J. Immunol. 153, 412-420 (1994).
37. + T cells. Immunity 15, 871-882 (2001).
38. Cannavo, G. et al. Abnormal intracellular kinetics of cell-cycle-dependent proteins in lymphocytes from patients infected with human immunodeficiency virus: a novel biologic link between immune activation, accelerated T-cell turnover, and high levels of apoptosis. Blood 97, 1756-1764 (2001).
39. Paiardini, M. et al. Exogenous interleukin-2 administration corrects the cell cycle perturbation of lymphocytes from human immunodeficiency virus-infected individuals. J. Virol. 75, 10843-10855 (2001).
40. + T lymphocytes in patients with AIDS. J. Immunol. 144, 1696-1704 (1990).
41. + T lymphocyte granules in lymphoid tissue during acute human immunodeficiency virus type 1 infection. J. Infect. Dis. 185, 1355-1358 (2002).
42. Kaech, S. M., Wherry, J. & Ahmed, R. Effector and memory T-cell differentiation: Implications for vaccine development. Nature Rev. Immunol. 2, 251-262 (2002).
43. Imami, N. et al. Immune responses and reconstitution in HIV-1 infected individuals: impact of antiretroviral therapy, cytokines and therapeutic vaccination. Immunol. Lett. 79, 63-76 (2001).
44. + T cells. J. Immunol. 158, 1551-1558 (1997).
45. + T cell: receptor-dependent cytolysis in the absence of interleukin-2 production. Science 251, 1228-1231 (1991).
46. + T cell approach feasible? Nature Rev. Immunol. 2, 283-291 (2002).
47. Cohen, O. J. et al. CXCR4 and CCR5 genetic polymorphisms in long-term nonprogressive human immunodeficiency virus infection: lack of association with mutations other than CCR5-Δ32. J. Virol. 72, 6215-6217 (1998).
48. Holmes, K., Fowlkes, B., Schmid, I. & Giorgi, J. in Current Protocols in Immunology Vol. 1 (eds. Coligan, J., Kruisbeek, A., Margulies, D., Sheevac, E. & Strober, W.) 5.3.1-5.3.23 (Green Publishing, New York, 1995).
49. Toba, K., Winton, E. F., Koike, T. & Shibata, A. Simultaneous three-color analysis of the surface phenotype and DNA-RNA quantitation using 7-amino-actinomycin D and pyronin Y. J. Immunol. Methods 182, 193-207 (1995).